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Background 
On January 14, 2005 the FDA Nonprescription 
and Endocrinologic & Metabolic Drugs Advisory 
Committees voted against the OTC marketing of 
lovastatin 20 mg (Mevacor Daily).  This follows a 
similar denial by the committees in July 2000 
when lovastatin 10 mg was proposed for OTC 
consideration.1 
 
The United Kingdom Model 
The model for OTC statin status was set in the 
United Kingdom (U.K.) with the approval of low-
dose Zocor Heart-Pro (simvastatin) this past July 
2004.  Zocor Heart-Pro 10 mg is available in a 
“behind the counter” status.  These restricted OTC 
products require patient-pharmacist interaction 
prior to the pharmacist providing the statin to a 
U.K. consumer.2  A similar process for the 
American Pharmacists Association’s (APhA’s) 
“Pharmacy Care OTCs” would include product 
placement and promotion requiring direct 
consumer-pharmacist interaction with supporting 
written information and guidance documents.  
Included in these activities are disease-risk 
assessment and monitoring.3,4   
In the U.K., simvastatin is considered suitable 
for patients with moderate risk of coronary heart 
disease.  Those individuals include men 55 to 70 
with or without risk factors, men 45 to 54 with 
one or more risk factors, and post-menopausal 
women 55 to 70 with one or more listed risk 
factors.  The risk factors include smokers, family 
history of early heart disease, being overweight or 
obese, and those of south Asian family origin.  
Their practice guidance document states that it is 
not necessary to have a patient’s cholesterol status 
to identify them as being at moderate risk and that 
it is possible to determine moderate risk through 
an individual’s self-reported risk factors.  It is 
suggested that a cholesterol test is a good practice 
as a baseline prior to therapy and then at least 
yearly thereafter.  Blood pressure measurement is 
not a required practice prior to starting therapy but 
is recommended.  Liver function testing is not 
required.  Pharmacists should be involved in the 
initial sales of simvastatin including discussion of 
risk factors, healthy lifestyle, contraindications, 
cautions, adverse effects, and drug interactions.  
Record keeping of sales and discussions is 
recommended.5
Prior to and after statin OTC status approval in 
the U.K., there were supporting and opposing 
comments, some of which were politically based.  
Others were related to the absence of clinical trials 
with the 10 mg dose of simvastatin and no trials in 
an OTC population.  Concern was also expressed 
that OTC statin presence would reduce healthy 
lifestyle changes.  A positive primary preventative 
measure is that the target population is below the 
threshold at which the National Health Service 
provides prescription statin therapy.6
 
The U.S. Decision 
The FDA Nonprescription and Endocrinologic 
& Metabolic Drugs Advisory Committees’ 
decision to reject Mevacor Daily’s OTC status 
and the immediate potential for any other OTC 
statin’s emergence, was based on the committees’ 
opinion that patients would have difficulty in the 
treatment self-selection process and potential 
inability to comply with long-term use and testing.  
Members described that the current OTC system 
is not adequate for this level of patient 
responsibility.  Many further indicated that they 
would have voted in favor of the OTC status if a 
“behind-the-counter” system as in the U.K. were 
available.  This was an undeclared vote in favor of 
APhA’s Pharmacy Care OTC proposal.  
Additional concerns were expressed relative to 
fetal risks associated with statins which carry a 
category X classification.7  This concern was 
evidenced by the committees lack of support for 
the self-diagnosis results of the Merck-sponsored 
study: A Consumer Use Study of Over-the-
More. . . 
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Counter Lovastatin (CUSTOM).1,8  They felt that 
the study did not adequately demonstrate 
lovastatin safety and efficacy in the OTC setting.  
The CUSTOM study’s target population was 
individuals with LDL-cholesterol in the 130 to 
170 mg/dL range.  It was a consumer driven and 
self-selection study open to consumers in an 
uncontrolled manner.  Participants self-selected 
and self-deselected themselves based on written 
guidelines and OTC Mevacor labeling.  The study 
evaluated the ability of participants to self-manage 
their therapy without pharmacist or other health 
care professional involvement.  The OTC 
Mevacor-consumer study demonstrated that the 
participants could appropriately self-select and 
self-manage their cholesterol over time.  Despite 
the study authors’ conclusions, the FDA 
committees did not feel that there was sufficient 
safety in this self-guided approach.1,8,9   
 
Pharmacy Care OTCs: A New Drug Class 
The CUSTOM study proposed a simulated 
OTC model for statins.  It was limited to a self-
selected population, did not evaluate clinical 
outcomes, and therefore did not demonstrate 
efficacy.8  Ultimately, it was not supported.1   
More. . . 
Statins are an ideal drug category for 
consideration as a new drug class model.  The 
APhA’s Pharmacy Care OTC model new drug 
class provisions provide the necessary safety and 
efficacy “frame” for statins.  This OTC model 
would fulfill the need to identify appropriate 
candidates for statin therapy.  Risk factor 
identification, family, medical, and concomitant 
therapy history, lifestyle and therapeutic 
education, adverse event prevention, and 
monitoring of treatment response for best 
outcomes would occur with the direct health care 
professional interaction proposed.  Primary 
prevention of cardiovascular events in patients 
without known CHD could be achieved for a 
greater percent of the population.   
Changes in U.S. federal statutes and 
regulations would be necessary to establish this 
new non-prescription drug class available only 
from pharmacists and other licensed health care 
professionals.10   
Alternately, OTC statins could be marketed as 
any other OTC product, as was proposed by 
Merck for their Mevacor Daily product, with 
appropriate consumer labeling and guidance 
documents.  Furthermore, manufacturers could 
label their proposed-statin OTC products with 
“behind-the-counter” storage requirements and 
suggested health care professional 
recommendations.10
In Canada, the National Association of 
Pharmacy Regulatory Authorities has a 
scheduling system for classification of 
medications.  Schedule I drugs require a 
prescription.  Schedule II therapies (“pharmacist 
only”) may be purchased over-the-counter but are 
stored in a non-public access area in the pharmacy 
and require professional intervention by a 
pharmacist at the point of sale.  Insulin and iron 
products with more than 30 mg elemental iron per 
dosage form are examples.  A third restricted 
OTC category, Schedule III (“pharmacy only”), is 
available only in a pharmacy so that the consumer 
may ask questions of the pharmacist.  The 
pharmacist assists the patient in selecting these 
medications.  Examples include Advil (ibuprofen) 
400 mg and Benadryl (diphenhydramine) 50 mg.  
With this drug scheduling system available in 
Canada, OTC statin placement will be favorable.11
 
 
Users of this document are cautioned to use their own 
professional judgment and consult any other necessary 
or appropriate sources prior to making clinical 
judgments based on the content of this document.  Our 
editors have researched the information with input 
from experts, government agencies, and national 
organizations.  Information and Internet links in this 
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